News Search Results
Jun 17, 2026, 08:00 ET Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress
in patients with known hypersensitivity to tacrolimus or to any of the ingredients in ENVARSUS XR.WARNINGS AND PRECAUTIONSLymphoma and Other Malignancies: Immunosuppressants, including ENVARSUS XR, increase the risk of developing lymphomas and other malignancies, particularly
More news about: Veloxis Pharmaceuticals
Jun 16, 2026, 08:00 ET 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
turn the human immune system into a powerful anti-cancer medicine, creating breakthrough treatments for malignant blood diseases such as leukemia, lymphoma, and multiple myeloma.The pioneering work in this field was fundamentally established by Dr. Steven A. Rosenberg, widely known as the "Father
More news about: The Tang Prize Foundation
Jun 15, 2026, 17:58 ET 美納里尼集團於 2026 年歐洲血液學協會 (EHA) 年會公佈 Selinexor 聯合 Ruxolitinib 治療骨髓纖維化的第 3 期 SENTRY 試驗數據
https://rarediseases.org/mondo-disease/myelofibrosis/2. Myelofibrosis. The Leukemia & Lymphoma Society (LLS).
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 07:40 ET El Grupo Menarini presenta datos del ensayo de fase 3 SENTRY de selinexor más ruxolitinib en mielofibrosis
https://rarediseases.org/mondo-disease/myelofibrosis/2. Myelofibrosis. The Leukemia & Lymphoma Society (LLS).
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 07:00 ET Il Gruppo Menarini presenta i dati dello studio di fase 3 SENTRY su selinexor più ruxolitinib nella mielofibrosi in occasione del Congresso 2026 dell'Associazione Europea di Ematologia (EHA)
https://rarediseases.org/mondo-disease/myelofibrosis/2. Myelofibrosis. The Leukemia & Lymphoma Society (LLS).
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 01:26 ET Menarini Group、European Hematology Association (EHA)の2026年総会にて、骨髄線維症を対象としたセリネキソールとルキソリチニブの併用療法に関する第3相SENTRY試験のデータを発表
https://rarediseases.org/mondo-disease/myelofibrosis/2. 骨髄線維症。The Leukemia & Lymphoma Society (LLS)。
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 21:25 ET 【EHA2026】亞盛醫藥多項臨床數據亮相，彰顯血液腫瘤領域全球創新實力
的療效和可控的安全性。CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY一項關鍵II期臨床研究中利沙托克拉（APG-2575）治療的慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者基線特徵與預後的相關性
More news about: 亞盛醫藥
Jun 14, 2026, 20:15 ET CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
Tmax of 10.5 days.Data for CT1190B in Relapsed/Refractory B-cell Non-Hodgkin's LymphomaA total of 13 patients (10 with large B-cell lymphoma [LBCL] and 3 with follicular lymphoma[FL]) received CT1190B infusion, with 1, 2, 4, and 6 patients dosed with 1.5×10⁸, 3.0×10⁸,
More news about: CARsgen Therapeutics
Jun 14, 2026, 13:17 ET 메나리니 그룹, 2026 유럽혈액학회(EHA) 학술대회에서 골수섬유증 대상 셀리넥서 및 룩소리티닙 병용요법의 제3상 SENTRY 시험 데이터 발표
https://rarediseases.org/mondo-disease/myelofibrosis/2. 골수섬유증. 백혈병•림프종 학회(The Leukemia & Lymphoma Society, LLS).
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:13 ET Menarini Group reporta datos del ensayo SENTRY de fase 3 de Selinexor Plus Ruxolitinib en mielofibrosis en el Congreso de la Asociación Europea de Hematología (EHA) 2026
https://rarediseases.org/mondo-disease/myelofibrosis/2. Mielofibrosis. The Leukemia & Lymphoma Society (LLS).
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:10 ET Grupo Menarini relata dados do Ensaio SENTRY de Fase 3 de Selinexor Plus Ruxolitinibe em mielofibrose no Congresso da Associação Europeia de Hematologia (EHA) 2026
https://rarediseases.org/mondo-disease/myelofibrosis/2. Mielofibrose. A Leukemia & Lymphoma Society (LLS).
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 07:26 ET Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
https://rarediseases.org/mondo-disease/myelofibrosis/2. Myelofibrosis. The Leukemia & Lymphoma Society (LLS).
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 03:15 ET Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.Adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
More news about: Eli Lilly and Company
Jun 12, 2026, 17:19 ET The Inner Circle acknowledges, Michael M. Pennock, MD, MBiot, DABR as a Pinnacle Lifetime Member
Oncology and the American College of Radiation Oncology. His commitment to giving back is reflected in his volunteer efforts with the Leukemia and Lymphoma Society's annual Light the Night event and his involvement with Connecting Champions, where he works with children recovering from cancer.Throughout
More news about: The Inner Circle
Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
leukopenia.1,2About VENCLYXTO VENCLYXTO® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis.
More news about: AbbVie
Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
leukopenia.1,2About VENCLYXTO VENCLYXTO® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis.
More news about: AbbVie
Jun 11, 2026, 14:00 ET Blood Cancer United Acquires Investigational Drug Supply to Preserve Access for Children with Rare, Fatal Leukemia
[email protected] Blood Cancer United®Blood Cancer United® (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. Since their founding in 1949, the organization
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Jun 11, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although ADC's treatment extended progression-free survival by 1.4 months, 27 deaths were recorded for those given Zynlonta, compared
More news about: Pomerantz LLP
Jun 09, 2026, 09:30 ET Lung Cancer Research Foundation Announces Request for Proposals Open for ALK-Positive Lung Cancer Research Grant
Research Foundation announced today that a new, two-year, $300,000 research award focused on accelerating treatment options for people with anaplastic lymphoma kinase (ALK) fusion-driven non-small cell lung cancer (NSCLC) is now open for investigator submission.
More news about: Lung Cancer Research Foundation
Jun 08, 2026, 14:45 ET FIU researchers find way to help cancer-fighting immune cells work longer and stronger
recognize cancer, and then put them back into the patient to attack tumors. The therapy has already helped many people with serious blood cancers like lymphoma and leukemia.But there is still a problem: cancer fights back.Tumors create a protective environment around
More news about: Florida International University
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
with:certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory) after 2 or more treatments.follicular lymphoma (FL) that has come back or that did not respond to previous treatment,
More news about: AbbVie
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
with:certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory) after 2 or more treatments.follicular lymphoma (FL) that has come back or that did not respond to previous treatment,
More news about: AbbVie
Jun 08, 2026, 07:30 ET Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
developing HyBryte™ (SGX301 or synthetic hypericin sodium), a photodynamic therapy utilizing visible light, for the treatment of cutaneous T-cell lymphoma (CTCL) in a Phase 3 study called "FLASH2" (Fluorescent Light Activated Synthetic Hypericin 2). The Data Monitoring Committee completed its interim
More news about: SOLIGENIX, INC.
Jun 04, 2026, 04:19 ET Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
forward, we will continue to advance clinical studies of rocbrutinib in other indications such as diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), to help more patients with various hematologic malignancies."Dr. Chen Yi, co-founder and CSO of
More news about: Lupeng Pharmaceutical Ltd
Jun 04, 2026, 00:30 ET Gujarat becomes the New Hub in Organ Transplantation
marrow, the spongy tissue within bones, is responsible for producing the blood cells that sustain life. When compromised by conditions such as leukaemia, lymphoma, aplastic anaemia, thalassaemia, or severe iron deficiency disorders, transplant can be curative. In India, the first bone marrow transplant was
More news about: Zydus Hospitals and Healthcare Research Private Limited